Argos Therapeutics, Inc. (ARGS) CSO Dr. Charles Nicolette To Join Panel Discussion On Challenges In Clinical Trial Development At The Society Of Gene & Cell Therapy Annual Meeting
5/20/2014 9:45:24 AM
DURHAM, N.C., May 19, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that company chief scientific officer and vice president of research and development Charles A. Nicolette, Ph.D., will participate in a panel discussion highlighting key issues in late stage development in gene and cell therapy. The discussion, entitled "Things you wish you'd known early on your way to late stage development," will take place on Friday, May 23, 2014, during the 17th Annual Meeting of the American Society of Gene & Cell Therapy at the Marriott Wardman Park Hotel in Washington, DC.
Help employers find you! Check out all the jobs and post your resume.
comments powered by